Literature DB >> 24858880

Quality of hepatitis C care at an urban tertiary care medical center.

Sabrina A Assoumou, Wei Huang, C Robert Horsburgh, Benjamin P Linas.   

Abstract

BACKGROUND: More effective treatment for hepatitis C virus (HCV) creates an opportunity to improve health outcomes.
OBJECTIVE: To use Centers for Medicare and Medicaid Services (CMS)-defined HCV quality indicators (QI) as a framework to assess the quality of care at an urban safety net hospital.
DESIGN: Retrospective cohort. PARTICIPANTS: Patients engaged in care (at least two outpatient visits, and minimum six-month follow-up time) between 2005 and 2011. Outcomes measures. 1) HCV ribonucleic acid (RNA); 2) genotyping; 3) treatment; and 4) Hepatitis A and B vaccination. Study time was divided into three periods: 1) 2005-2006, 2) 2007-2008, 3) 2009-2011. Key results. Number who met inclusion criteria: 3,018; 13% were human immunodeficiency virus co-infected. Only 1% completed the care recommended in the CMS quality indicators that were evaluated. Later time periods were independently associated with greater rates (aHR for HCV testing, 1.15; 95% CI, 1.04-1.28).
CONCLUSIONS: Quality of care is improving, but it remains suboptimal. Initiatives are needed to increase QI completion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24858880      PMCID: PMC4541792          DOI: 10.1353/hpu.2014.0093

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  16 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.

Authors:  Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

3.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

4.  Academic health center management of chronic diseases through knowledge networks: Project ECHO.

Authors:  Sanjeev Arora; Cynthia M A Geppert; Summers Kalishman; Denise Dion; Frank Pullara; Barbara Bjeletich; Gary Simpson; Dale C Alverson; Lori B Moore; Dave Kuhl; Joseph V Scaletti
Journal:  Acad Med       Date:  2007-02       Impact factor: 6.893

5.  Boston Patient Navigation Research Program: the impact of navigation on time to diagnostic resolution after abnormal cancer screening.

Authors:  Tracy A Battaglia; Sharon M Bak; Timothy Heeren; Clara A Chen; Richard Kalish; Stephen Tringale; James O Taylor; Barbara Lottero; A Patrick Egan; Nisha Thakrar; Karen M Freund
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10       Impact factor: 4.254

6.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

7.  FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

Authors:  Anaïs Vallet-Pichard; Vincent Mallet; Bertrand Nalpas; Virginie Verkarre; Antoine Nalpas; Valérie Dhalluin-Venier; Hélène Fontaine; Stanislas Pol
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

8.  Changing trends in hepatitis C-related mortality in the United States, 1995-2004.

Authors:  Matthew Wise; Stephanie Bialek; Lyn Finelli; Beth P Bell; Frank Sorvillo
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

9.  Treatment of hepatitis C infection for current or former substance abusers in a community setting.

Authors:  A John-Baptiste; M Varenbut; M Lingley; T Nedd-Roderique; D Teplin; G Tomlinson; J Daiter; M Krahn
Journal:  J Viral Hepat       Date:  2009-02-23       Impact factor: 3.728

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  2 in total

1.  Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.

Authors:  Katelyn J Carey; Wei Huang; Benjamin P Linas; Judith I Tsui
Journal:  J Subst Abuse Treat       Date:  2016-02-13

2.  Relationship between hepatitis C clinical testing site and linkage to care.

Authors:  Sabrina A Assoumou; Wei Huang; C Robert Horsburgh; Mari-Lynn Drainoni; Benjamin P Linas
Journal:  Open Forum Infect Dis       Date:  2014-05-14       Impact factor: 4.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.